Currently in a phase II open trial that will end in 2-3 years. Additional trials, registrational trials if successful. Ten years to approval and those 15% payments. Do you expect CDMO to be around in ten years?
Laura Benjamin recent interview 27 minutes as she discusses IP assets part of 15% net sales heading to Avid Bioservices CDMO ( Varisacumab and Bavituximab ) She says in the interview an assay completed for diagnostic re: Varisacumab and very interesting ....also clear out admits she was impressed with how it was Bavituximab that led to MOS when patients moved on to another treatment ( which is what Merck seen with Keytruda) and ex Eli Lilly = Alex Azar ...now US Secretary of State Department Health Human Services knows well due to complaints filed to FDA to release the info and have Bavi approved
Everyone needs it ...all Big Pharma and even Lockheed Martin that filed for a PS Targeting patent to use Perforene (graphene) filter to extract SUBSTANCES out of blood
The ONLY bad substances on stressed cells contain flipped PS and Dr Laura Benjamin states that all stressed cells HAVE flipped PS and there is SO much more being gathered collected and submitted ...maybe our Chair Joseph Carleone had ties with Byron ties over at Keystone etc : )
Altravue Capital knows Richard Aldrich and family ...new NEW ISS prepared now although some request I stop giving out free for all but since I say trust no one...all will have it
____
Graphene-based filter for isolating a substance from blood
Filed = June 21, 2013
Awarded = Feb 21, 2017 (Stafford shows up)
A device isolates a substance from blood. The substance includes particles with an effective diameter that is within a range defined by effective diameters of constituents of blood. The device comprises a first sheet of graphene including a first plurality of apertures. The first plurality of apertures are configured to pass objects with an effective diameter less than or equal to the effective diameter of the particles of the substance. The device comprises a second sheet of graphene including a second plurality of apertures. The second plurality of apertures are configured to pass objects with an effective diameter less than the effective diameter of the particles of the substance. The device may be configured to include a conduit system. The device may be configured to operate according to a reversible cycle.
This stock is broken. Markets keep setting new highs and we are dropping. So tired of this. Thought once we went to a boring CDMO we’d at least be on a slow steady climb to a reasonable value.
News 
Market Data 
Discover 
